On December 22, BioHeng, an innovative biotechnology company focusing on general cell therapy, and Genscript, a global outstanding biomedical CRO company, jointly announced that the two parties have reached cooperation on the development and production of key raw materials in the field of cell therapy and gene therapy. The goal is to accelerate The commercialization process of universal cell therapy.
Autologous CAR-T products have a long preparation cycle, difficult to guarantee product consistency, and high treatment costs for clinical applications that have always been pain points. Universal CAR-T cells obtain allogeneic T cells and delete genes that may cause graft-versus-host disease (GvHD), thereby making it possible to produce CAR-T cell therapeutic products on a spot scale.
Recently, BioHeng’s self-developed cell product CTA101 submitted an IND application to CDE, which is expected to become a “first in class” universal cell therapy product in China. CTA101 is a dual-target universal CAR-T cell therapy based on CRISPR/Cas9 gene editing program developed by BioHeng's first-generation universal CAR-T technology platform, "off-the-shelf", anti-CD19/CD22 dual-target universal CAR-T cell therapy. It can be used to treat relapsed/refractory B-cell acute lymphoblastic leukemia.
In recent years, BioHeng has been focusing on the research and development and production of cell and gene drugs. It has original technological breakthroughs in both general-purpose and solid tumor immune cell therapy and has achieved proud results. BioHeng has been looking forward to quickly bringing more products to the clinic, in order to solve the bottleneck of immune cell therapy drugs, improve safety and effectiveness, while reducing costs, and finally achieve accessibility to every patient and provide patients worldwide Cell and gene therapy drugs that can afford medical costs truly benefit cancer patients.
The key raw material for universal CAR-T cells
CRISPR gene editing technology is an important step in the knockout of graft-versus-host disease (GvHD)-related genes in the preparation of universal CAR-T cells. Gene editing reagents, as the key raw materials, are critical to product quality and efficacy. Relying on 20 years of experience in chemical synthesis of nucleic acid raw materials, Genscript provides BioHeng with sgRNA, a key gene editing reagent raw material that matches clinical research and application requirements, customized quality control testing and professional service support.
Based on this strategic cooperation, Genscript will concentrate professional R&D and production team resources to provide comprehensive support for BioHeng's projects more efficiently, and use high-standard gene editing reagent materials to escort downstream high-quality cell therapy products.
At the same time, the two parties will carry out all-round cooperation in the development of key raw material industry standards in the field of gene cell therapy, and contribute wisdom and strength to accelerate the commercialization of general-purpose cellular immunotherapy products and benefit cancer patients.
Mr. Yanbin Wang, COO of BioHeng, said: China is currently in the golden age of biomedicine development. BioHeng has been exploring and intensively working on the development of innovative drugs. This time, BioHeng will use the high-standard and high-quality key gene editing reagent materials provided by Genscript to continuously improve its technology and innovation capabilities to advance the process of BioHeng's research and development and production. During the cooperation with Genscript, BioHeng felt Genscript's ingenuity in the production process. BioHeng looks forward to working with Genscript to establish stable and long-term in-depth cooperation, and work together to build an industrial ecosystem and promote the rapid development of the industry.
Genscript COO Ms. Shao Weihui said: Thank you BioHeng for your trust and support to Genscript, and she is very happy to support each other and make progress together with such an excellent team as BioHeng. Genscript has always adhered to the "customer first" philosophy, constantly innovating and making progress around customer needs, and continuously upgrading from supporting early-stage scientific research to matching downstream applications. Gene cell therapy is the strategic direction of Genscript's key layout. Genscript looks forward to contributing its strength in this field with high-quality services and products, and fulfilling its corporate mission of "using biotechnology to make people and nature healthier".